Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Myelodysplastic Syndromes 14Leukemia, Myeloid, Acute 13Multiple Myeloma 12Leukemia 12Lymphoma 11Hodgkin Disease 10Hematologic Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Graft vs Host Disease 8Leukemia, Myeloid, Accelerated Phase 7Blast Crisis 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms, Plasma Cell 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelomonocytic, Chronic 3Congenital Abnormalities 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Recurrence 2Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Myelodysplastic-Myeloproliferative Diseases 2Mycosis Fungoides 2

Interventions

Tacrolimus 1Ointments 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Cancer Lymphedema × Tacrolimus × Clear all
NCT04541290 2022-02-09

Tacrolimus as Treatment of Breast Cancer-Related Lymphedema

Odense University Hospital

Phase 1/2 Completed
20 enrolled
Breast

Breast Cancer Lymphedema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡